Eli Lilly & Co. (LLY) Announces CYRAMZA Phase 3 REACH Primary Endpoint Not Statistically Significant
Tweet Send to a Friend
Eli Lilly & Co. (NYSE: LLY) announced that The Lancet Oncology has published results of the Phase III REACH trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE